Melanotan II raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
== Genetics == The gene for G-CSF is located on chromosome 17, locus q11.2-q12. Nagata et al. found that the GCSF gene has four introns, and that two different polypeptides are synthesized from the same gene by differential splicing of mRNA. The two polypeptides differ by the presence or absence of three amino acids. Expression studies indicate that both have authentic GCSF activity. It is thought that stability of the G-CSF mRNA is regulated by an RNA element called the G-CSF factor stem-loop destabilising element.
=== Nathan: The Big Nasty Bully === First aired: 17 September 2009 Victims Martin and Adesh have a big problem with big bully Nathan. He's made their lives miserable and have the physical and emotional scars to prove it. Mayhem calls upon legendary MMA fighter, Andrei Arlovski to clean this bully's clock. He was knocked out and submitted five times. Nathan's taunting of Arlovski only makes his beating worse. Martin and Adesh won $10,000.
== Function == Tendon cells are primarily responsible for the production and maintenance of the tendon extracellular matrix (ECM), which consists mainly of collagen fibers. These cells are involved in synthesizing collagen and other ECM components that provide tendons with tensile strength. Tendon cells also participate in remodeling the ECM in response to mechanical stress and injury.
Professor Sarbolouki was the editor of Molecules, an international journal devoted to synthetic organic chemistry and natural product chemistry. He was also chief editor of Iranian Journal of Chemistry & Chemical Engineering. Professor Sarbolouki died on September 1, 2009, and his body was buried in Tehran Cemeteries, at the block for national legends on September 2, 2009. The Vice President and Minister of Science delivered messages of condolence and his burial was attended by numerous Iranian academics, scholars and students.
Guttenplan (1978), London correspondent and current editor of The Nation Michael Musto (1978), gossip columnist for The Village Voice Andrea di Robilant (1979), Italian journalist for La Stampa and professore Tim Weiner (1979), Pulitzer Prize-winning reporter for The New York Times specializing in national security matters Kevin Baker (1980), freelance journalist and novelist John Leland (1981), journalist for The New York Times Jason Zweig (1982), financial journalist and columnist for The Wall Street Journal Barry C. Lynn (1983), journalist, senior fellow at the New America Foundation Ashley Kahn (1983), Grammy-winning music historian, journalist, and producer Daniel Wattenberg (1983), journalist for The Washington Times, son of neoconservative pundit Ben J. Wattenberg N.J.
Sources: en.wikipedia.org
== Pathophysiology == Chronic wounds may affect only the epidermis and dermis, or they may affect tissues all the way to the fascia. They may be formed originally by the same things that cause acute ones, such as surgery or accidental trauma, or they may form as the result of systemic infection, vascular, immune, or nerve insufficiency, or comorbidities such as neoplasias or metabolic disorders. The reason a wound becomes chronic is that the body's ability to deal with the damage is overwhelmed by factors such as repeated trauma, continued pressure, ischemia, or illness. Though much progress has been accomplished in the study of chronic wounds lately, advances in the study of their healing have lagged behind expectations. This is partly because animal studies are difficult because animals do not get chronic wounds, since they usually have loose skin that quickly contracts, and they normally do not get old enough or have contributing diseases such as neuropathy or chronic debilitating illnesses. Nonetheless, current researchers now understand some of the major factors that lead to chronic wounds, among which are ischemia, reperfusion injury, and bacterial colonization.
== Operations == As of 2025, KEZAD Group’s infrastructure and services span 12 economic zones across Abu Dhabi, Al Ain and Al Dhafra Region, as well as an industrial and logistics zone in East Port Said, Egypt, covering a total area of 570 sq km. KEZAD Group’s platform supports over 2,300 businesses across 17 economic sectors, including logistics, automotive, food and beverages, pharmaceuticals, metals, chemicals, packaging, and clean energy industries.
Gorgonzola blue cheese takes its name from the village of Gorgonzola in Italy where it was first made. Belonging to the family of Stracchino cheeses, Gorgonzola is a whole milk, white, and "uncooked" cheese. This blue cheese is inoculated with Penicillium glaucum which, during ripening, produces the characteristic of blue-green veins. There are two variants with different odor: natural and creamy Gorgonzola. 63 components in natural Gorgonzola cheese and 52 components in creamy Gorgonzola cheese contribute to odor with 2-nonanone, 1-octen-3-ol, 2-heptanol, ethyl hexanoate, methylanisole and 2-heptanone being the prominent compounds for odor in both cheeses.
CH2O + HCN + NH3 → NH2-CH2-CN (aminoacetonitrile) + H2O NH2-CH2-CN + 2H2O → NH3 + NH2-CH2-COOH (glycine) Furthermore, water and formaldehyde can react via Butlerov's reaction to produce various sugars like ribose. The experiments showed that simple organic compounds, including the building blocks of proteins and other macromolecules, can abiotically be formed from gases with the addition of energy.
Sources: en.wikipedia.org
==== Electronic Health Records ==== Sharing their electronic health records with people who have T2D helps them to reduce their blood sugar levels. It is a way of helping people understand their own health condition and involving them actively in its management.
In 1945, Yeshiva University President Samuel Belkin began planning a new medical school. Under his urging, Yeshiva's Board of Trustees negotiated with the New York State Board of Regents to expand the university's charter to grant MD degrees, finalized in December 1950. In 1951, physicist Albert Einstein wrote a letter to Belkin lauding the planned school, writing that it was "of the greatest importance to American Jewry" and would "welcome students of all creeds and races". He became an honorary chairman for the medical school campaign, alongside former First Lady Eleanor Roosevelt, New York Governor Thomas Dewey, and Richard Nixon. When approached, Einstein was initially reluctant to associate his name with the school—he had recently refused to lend his name to Brandeis University and had declined to become the second president of Israel—and instead suggested that it be named for the Jewish physician Maimonides. Two years later, at an event marking his 74th birthday, March 14, 1953, Einstein agreed to lend his name to the medical school. At the gathering—his only public appearance in 22 years at the Institute for Advanced Study—Einstein told The New York Times that "physics has favored medicine by giving civilized man confidence in the scientific method." In 1954, the college sponsored the awarding of that year's Albert Einstein Award to physicist Richard Feynman and, on his 75th birthday, gifted Einstein a Festschrift with contributions from ten Nobel laureates, Israeli Prime Minister Moshe Sharett, and President Harry S. Truman, among others.
EiPLA, also known as N-ethyl-N-isopropyllysergamide or as lysergic acid ethylisopropylamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is an isomer of ETH-LAD.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.